Fmr LLC doubles down on AI plumbing and adds a pharma safety net

The biggest incremental bet is on the enablers of AI and cloud scale, not just the front‑end platforms.

• NVIDIA: Despite enormous embedded gains (up 3348.9% versus average cost), Fmr LLC increased the position by an estimated $4.0B. That says they see the GPU supply/demand imbalance and AI training spend as having further to run, and are willing to lean into their winner instead of trimming it as a source of liquidity.

• Amazon: An estimated $5.7B add and an 8.2% increase in shares signals rising conviction in AWS and logistics leverage. With the position now 3.94% of the book, they are betting that cloud plus retail efficiencies still compound from here.

• KLAC and Lam Research: KLA’s stake was ramped 73.0% (about $2.7B more), and Lam Research rose 25.8% (roughly $1.5B). This is a clear call that the AI and advanced node capex cycle will flow disproportionately to process control and wafer‑fab equipment, not just to the headline chip designers.

• Arista Networks and Cisco: Arista’s share count jumped 34.0% (about a $1.6B add), and Cisco was lifted 3.0%. These are classic AI networking winners; Fmr LLC is effectively saying bandwidth and low‑latency switching remain bottlenecks in data center build‑outs.

• Berkshire Hathaway B: A 58.1% add to BRK.B, or about $2.6B, looks like a deliberate quality anchor alongside the growth book. It’s a way to keep exposure to U.S. industrial and financial earnings while outsourcing stock‑picking to Berkshire’s own capital allocation machine.

• Big pharma: The new $5.8B position in AstraZeneca, alongside adds to Eli Lilly, Merck and Johnson & Johnson, builds a sizable pharma sleeve. AZN’s fresh 0.31% weight plus Merck (+9.0% shares) and a 31.9% jump in J&J signal a barbell: obesity and oncology upside via Lilly and AstraZeneca, wrapped in more diversified pharma franchises for downside protection.

If the buys tell you where Fmr LLC wants to be for the next five years, the trims tell you what they no longer need.

• Early AI hardware winners: Micron and SanDisk both saw heavy selling. Micron’s shares were cut 19.0% (around a $2.5B reduction) despite a 935.3% gain versus cost, and SanDisk was slashed by 37.6% (about $5.1B). That looks like pruning the highest‑beta parts of the memory trade after a huge run, and rotating into steadier semicap and networking exposure.

• Megacap software and ads: Microsoft and Meta were clipped by 5.3% and 4.7%, respectively, with Microsoft’s estimated reduction at $4.0B and Meta’s at $3.3B. This is not an abandonment — both remain core positions — but a subtle downgrade of megacap software/ads as the purest AI vehicle in favor of the capex supply chain.

• Legacy quality and spin‑offs: The BRK.A stake was cut by 30.8% (roughly $5.4B), while BRK.B was increased, effectively migrating exposure from the expensive A line into the more flexible B line. GE Vernova and GE Aerospace were both trimmed, signaling less enthusiasm for the post‑breakup story now that much of the restructuring upside is recognized.

• Banks and payments: Wells Fargo (-12.9% shares), JPMorgan (-12.0%) and Bank of America (-7.6%) were all reduced, and both Visa and Mastercard were gently trimmed. The pattern is consistent: lighten up on rate‑sensitive and consumer‑cycle financials as a funding source for secular growth and healthcare, without exiting the themes entirely.

• Optical and telecom equipment: Lumentum was cut sharply, down 23.0% (about a $1.5B reduction). Fmr LLC seems to be concentrating its networking risk in Arista and Cisco rather than more volatile optical names.

On the surface, technology’s share of the book barely moved, slipping from 63.75% to 62.97%. Underneath, the exposure is being rewired away from generalized tech beta and toward the AI infrastructure stack.

Within tech, capital is migrating from memory (Micron, SanDisk) and some legacy hardware toward semicap (KLA, Lam Research), GPUs (NVIDIA), and networking (Arista, Cisco). That’s a conscious tilt toward the vendors that benefit most directly from hyperscale data center capex, rather than from downstream software monetization debates.

Outside tech, two sectors quietly matter more. Health care jumped from 4.82% to 5.77% on the back of the new AstraZeneca stake and adds in Merck, J&J, Eli Lilly and Gilead. Consumer discretionary crept up from 9.92% to 10.64% as Amazon, Netflix and Lowe’s all grew, suggesting continued faith in U.S. consumer and digital spending.

Meanwhile, finance drifted down from 3.51% to 3.11% as big banks were trimmed; real exposure is likely even lower once you look through Berkshire’s conglomerate mix. Energy nudged up from 3.81% to 3.93% via incremental Exxon and stable Shell/Imperial positions, a modest hedge against inflation and geopolitical risk rather than a core bet.

Put together, Fmr LLC is positioning for an environment where AI‑driven capital spending and U.S. consumer strength keep compounding, but macro and valuation risk can’t be ignored.

The house view appears to be that the AI build‑out remains in the early innings, with greatest operational leverage accruing to GPU suppliers, semicap, and high‑end networking rather than to the mega‑platforms alone. By recycling capital out of Micron, SanDisk, Microsoft and Meta into KLA, Lam, Arista and even more NVIDIA, they are sharpening that bet.

At the same time, the build‑out of a sizeable pharma cluster — AstraZeneca, Eli Lilly, Merck, J&J, Gilead — and the increased stake in Berkshire Hathaway B look like deliberate volatility dampers after a tough -8.56% quarter. Those positions add defensiveness and idiosyncratic pipelines that don’t live or die on the same economic cycle as semis and consumer internet.

Going forward, expect this book to continue rotating within technology rather than away from it: more focus on AI infrastructure, less on commoditized or lower‑ROIC hardware. The trims in banks, payments and select industrials suggest that if they need more fuel for those themes, it will likely come from macro‑sensitive cyclicals, not from their highest‑conviction secular growers.